PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - PTC Therapeutics reported a revenue of $213.17 million for the quarter ended December 2024, reflecting a 30.6% decrease year-over-year and a 3.96% miss against the Zacks Consensus Estimate of $221.96 million [1] - The company's EPS was -$0.24, unchanged from the previous year, but exceeded the consensus estimate of -$0.96 by 75% [1] Revenue Breakdown - Net product revenue was $154.71 million, slightly above the estimated $141.85 million, but down 0.2% from the same quarter last year [4] - Royalty revenue reached $58.16 million, below the estimated $73.16 million, but showed a year-over-year increase of 14.1% [4] - Emflaza's net product revenue was $50.50 million, slightly below the estimate of $50.95 million, marking a significant decline of 25.1% year-over-year [4] - Translarna's net product revenue was $93.70 million, surpassing the average estimate of $78.77 million, with a year-over-year growth of 24.6% [4] Stock Performance - PTC Therapeutics shares have increased by 12.7% over the past month, contrasting with a 2.2% decline in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]